Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Return on Invested Capital (2019 - 2023)

Denali Therapeutics (DNLI) has disclosed Return on Invested Capital for 5 consecutive years, with 0.18% as the latest value for Q4 2023.

  • On a quarterly basis, Return on Invested Capital rose 18.0% to 0.18% in Q4 2023 year-over-year; TTM through Dec 2023 was 0.18%, a 18.0% increase, with the full-year FY2024 number at 0.43%, down 24.0% from a year prior.
  • Return on Invested Capital was 0.18% for Q4 2023 at Denali Therapeutics, down from 0.15% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.06% in Q4 2020 to a low of 0.51% in Q4 2019.
  • A 5-year average of 0.23% and a median of 0.24% in 2023 define the central range for Return on Invested Capital.
  • Peak YoY movement for Return on Invested Capital: skyrocketed 57bps in 2020, then plummeted -39bps in 2022.
  • Denali Therapeutics' Return on Invested Capital stood at 0.51% in 2019, then skyrocketed by 112bps to 0.06% in 2020, then crashed by -590bps to 0.3% in 2021, then decreased by -22bps to 0.37% in 2022, then surged by 50bps to 0.18% in 2023.
  • Per Business Quant, the three most recent readings for DNLI's Return on Invested Capital are 0.18% (Q4 2023), 0.15% (Q3 2023), and 0.37% (Q4 2022).